Arimidex (ZD1033): A selective, potent inhibitor of aromatase in post-menopausal female volunteers

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 543-548

  Yates, R A ^a   Dowsett, M ^b   Fisher, G V ^a   Selen, A ^c   Wyld, P J ^d  

^a ASTRAZENECA   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Zeneca Pharmaceuticals   (United States)

^d Inveresk Clinical Research Ltd   (United Kingdom)

Author keywords

Arimidex; Aromatase inhibitor; Oestrogen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CORTICOSTEROID; CORTICOTROPIN; ESTRADIOL; GONADOTROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; ENDOCRINOLOGY; ESTRADIOL BLOOD LEVEL; FEMALE; GONADOTROPIN BLOOD LEVEL; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADRENOCORTICOTROPIC HORMONE; AROMATASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ESTRADIOL; ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HORMONES; HUMANS; HYDROCORTISONE; LUTEINIZING HORMONE; NITRILES; POSTMENOPAUSE; STEROIDS; TRIAZOLES;

EID: 0030040104     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.94     Document Type: Article

References (16)

1. DEMERS LM, LIPTON A, HARVEY HA, HANAGHAN J, MALAGHA M AND SANTEN RJ. (1993). The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J. Steroid Biochem. Mol. Biol., 44, 683-685.
2. DOWSETT M, GOSS PE, POWLES TJ, HUTCHINSON G, BRODIE AM, JEFFCOATE SL AND COOMBES RC. (1987). Use of the aromatase inhibitor 4-hydroxyandrostenedione in post-menopausal breast cancer: optimisation of therapeutic dose and route. Cancer Res., 47, 1957-1961.
3. GOSS PE, GWYNN KMEH. (1994). Current perspectives on aromatase inhibitors in breast cancer. J. Clin. Oncol., 12, 2460-2470.
4. HARRIS AL, DOWSETT M, JEFFCOATE SL AND SMITH IE. (1983). Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur. J. Clin. Oncol., 19, 493-498.
5. HOFFKEN K. (1993). Experience with aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev., 19, 37-44.
6. HOFFKEN K, JONAT W, POSSINGER K, KOLBEL M, KUNZ T, WAGNER H, BECHER R, CALLIES R, FRIEDERICH P, WILLMANNS W, MAASS H AND SCHMIDT CG. (1993). Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of post-menopausal patients with advanced breast cancer: a phase II study. J. Clin. Oncol., 8, 875-880.
7. IVESON TJ, SMITH IE, AHERN J, SMITHERS DA, TRUNET PF AND DOWSETT M. (1993). Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in post menopausal patients with breast cancer. Cancer Res., 53, 266-270.
8. JOHNSTON SRD, SMITH IE, DOODY D, JACOBS S, ROBERTSHAW H AND DOWSETT M. (1994). Clinical and endocrine effects of the oral aromatase inhibitor vorozole in post-menopausal patients with advanced breast cancer. Cancer Res., 54, 5875-5881.
9. LONNING PE AND JOHANNESSEN DC. (1991). Treatment of breast cancer with aromatase inhibitors. Drugs Today, 21, 117-132.
10. MILLER BA. (1991). Causes of breast cancer and high risk groups. In Breast Diseases, Harris JR, Hellman S, Henderson IC, Kinne DW (eds) pp. 119-126. JB. Lippincott: New York.
11. MILLER WR. (1989). Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev., 16, 83-93.
12. MUSS HB. (1992). Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat., 21, 15-26.
13. PLOURDE PV, DYROFF M AND DUKES M. (1994). ARIMIDEX(TM): a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat., 30, 103-111.
14. SANTEN RJ. (1991). Clinical use of aromatase inhibitors in human breast carcinoma. J. Steroid Biochem. Mol. Biol., 40, 247-253.
15. SANTEN RJ, DEMERS LM, LYNCH J, HARVEY H, LIPTON A, MULAGHA M, HANAGHAN J, GARBER JE, HENDERSON IC, NAVARI RM AND MILLER AA. (1991). Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J. Clin. Endocrinol. Metab., 73, 99-106.
16. STEIN RC, DOWSETT M, HEDLEY A, DAVENPORT J, GAZET T, FORD HT AND COOMBES RC. (1990). Treatment of advanced breast cancer in post-menopausal women with 4-hydroxyandrostenedione. Cancer Chemother. Pharmacol., 26, 75-78.